We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

84 hedge funds and large institutions have $79.1M invested in Zynerba Pharmaceuticals, Inc in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 13

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

11% more funds holding

Funds holding: 76 → 84 (+8)

1% less call options, than puts

Call options by funds: $6.27M | Put options by funds: $6.32M

31% less capital invested

Capital invested by funds: $115M → $79.1M (-$36.2M)

Holders
84
Holders Change
+8
Holders Change %
+10.53%
% of All Funds
1.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
35
Reduced
13
Closed
9
Calls
$6.27M
Puts
$6.32M
Net Calls
-$49K
Net Calls Change
-$1.65M

Top Buyers

Rank Fund Capital Flow
1
EMG
ETF Managers Group
New Jersey
+$4.98M
2
JP Morgan Chase
JP Morgan Chase
New York
+$2.51M
3
Northern Trust
Northern Trust
Illinois
+$2.43M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.97M
5
PCM
Portolan Capital Management
Massachusetts
+$1.7M

Top Sellers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
-$745K
2
Barclays
Barclays
United Kingdom
-$526K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$240K
4
HighTower Advisors
HighTower Advisors
Illinois
-$227K
5
RJA
Raymond James & Associates
Florida
-$167K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIC
76
Ameritas Investment Company
Nebraska
$3K +$4.55K +404 New
CAPTRUST Financial Advisors
77
CAPTRUST Financial Advisors
North Carolina
$1K – – –
CFD
78
Creative Financial Designs
Indiana
$1K – – –
HR
79
Howe & Rusling
New York
$1K – – –
KTC
80
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
US Bancorp
81
US Bancorp
Minnesota
$1K – – –
PHK
82
Point72 Hong Kong
Hong Kong
$1K +$789 +70 New
SFS
83
Sowell Financial Services
Arkansas
$1K +$902 +80 New
RJA
84
Raymond James & Associates
Florida
– -$167K -12,305 Closed
MIM
85
MetLife Investment Management
New Jersey
– -$150K -11,100 Closed
MLICM
86
Metropolitan Life Insurance Company (MetLife)
New York
– -$23.7K -1,751 Closed
CAC
87
Certified Advisory Corp
Florida
– -$20K -1,443 Closed
DWA
88
Dorsey Wright & Associates
California
– -$11K -804 Closed
Fidelity Investments
89
Fidelity Investments
Massachusetts
– -$8K -600 Closed
YWP
90
YorkBridge Wealth Partners
New York
– -$5K -400 Closed
GWM
91
Geneos Wealth Management
Colorado
– -$1K -100 Closed
SSB
92
Sandy Spring Bank
Maryland
– -$1K -50 Closed
1 2 3
4

ZYNE Hedge Fund Activity: Q3 2019 in Review

84 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2019, worth a combined $79.1M — down 31% from $115M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new ZYNE positions and 9 closed out — a net gain of 8 holders — while 35 added to existing stakes and 13 trimmed.

The largest buyer was ETF Managers Group, adding an estimated $4.98M. The largest seller was Group One Trading, cutting an estimated $745K.

  • 84 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2019, up from 76 in Q2 2019.
  • Funds reported $79.1M of Zynerba Pharmaceuticals, Inc stock for Q3 2019, down 31% quarter-over-quarter.
  • 17 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2019 and 9 closed out, a net change of +8 holders.
  • The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2019 was ETF Managers Group, an estimated $4.98M added.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q3 2019 was Group One Trading, an estimated $745K sold.

Based on aggregated 13F filings for Q3 2019.